The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Keldeagh Lindsay

Monday Biotech Deal Review: June 11, 2012

Welcome to your Monday Biotech Deal Review for June 11, 2012.  The Monday Biotech Deal Review is back with Norton Rose Canada summer law student Jennifer Ng, who has agreed to assist with the deal review over the summer months.  A very warm thanks to Keldeagh Lindsay for his dedication and contribution to the blog!  The below covers transactions in the biotech space since since May 14, 2012.  Highlights include the closing of the first tranche of Stellar Pharmaceuticals’ debt financing, as well as private placements each worth approximately $6 million closed for each of MedMira Inc. and Lorus Therapeutics.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 30, 2012

Welcome to your Monday Biotech Deal Review for April 30, 2012.  It was a slow week last week, with a couple of private placement closings, a business unit purchase and some commercial activity.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 2, 2012

Welcome to your Monday Biotech Deal Review for April 2, 2012.  There have been few large transactions over the previous weeks, but there have been some private placement financings and M&A activity, including the announcement of a takeover by Valeant of Russian-based Natur Product International for approximately $180M.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 23, 2012

Welcome to your Monday Biotech Deal Review for January 23, 2012.  Noteworthy news from the previous week include the sweetening of the offer by Valeant for ISTA Pharmaceuticals by an additional dollar per share ($7.50 from $6.50), and the adoption by ISTA of a shareholder rights plan to replace its recently expired plan.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: November 14, 2011

Welcome to your Monday Biotech Deal Review for November 14, 2011, marking the end of its one month hiatus.  The Monday Biotech Deal Review will now be resuming its normal weekly schedule.  Below are summaries of recent transactions over the past month, which includes the acquisition of Afexa by Valeant for $0.85 per Afexa share, in cash.    Read on to learn more.  Read more of this post

Monday Biotech Deal Review: September 12, 2011

Welcome to your Monday Biotech Deal Review for September 12, 2011.  We hope everyone had a restful labo(u)r day long weekend, both north and south of the border.  This week’s biotech deal review is a double feature owing to last week’s holiday.  There has been a lot of activity in the past two weeks, including the announcement of a friendly takeover bid of Afexa by Valeant (Afexa is already the target of a hostile bid by Paladin).  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: August 29, 2011

Welcome to your Monday Biotech Deal Review for August 29, 2011.  In addition to the usual private placement announcements and various commercial transactions, the ongoing hostile bid for Afexa Life Sciences was in the news, with the board of Afexa confirming its recommendation to shareholders to not tender their shares pursuant to the unsolicited bid by Paladin Labs.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: August 22, 2011

Welcome to your Monday Biotech Deal Review for August 22, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP articling student Keldeagh Lindsay, who will be with us during his articles and assisting in the deal review.  Steven Zuccarelli has done a great job over the summer, and we wish him well in his final year at law school.  

There has been quite a lot of activity over the previous two weeks, with significant equity investment activity, debt financings (public and private), and mergers and acquisitions on the go.  Read on to learn more. Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 126 other followers